IP Library Granted Patent US 7,645,860
Granted Patent B2
US 7,645,860 · App. 12/184,567 · Granted Jan 12, 2010

Factor VIII polymer conjugates

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,645,860
App. No.
12/184,567
Granted
Jan 12, 2010
Kind
B2
Abstract

The invention is a proteinaceous construct comprising a Factor VIII molecule which is conjugated to a water-soluble polymer via carbohydrate moieties of Factor VIII, and methods of preparing same.

Claims (12)

1. A method of conjugating a water soluble polymer to an oxidized carbohydrate moiety of Factor VIII comprising contacting the oxidized carbohydrate moiety with an activated water soluble polymer under conditions that allow conjugation, wherein said FVIII that has been conjugated to the water soluble polymer retains at least 50% of native FVIII activity.

2. The method according to claim 1 wherein the water soluble polymer is selected from the group consisting of PEG, PSA and dextran.

3. The method according to claim 1 wherein the activated water soluble polymer is selected from the group consisting of PEG-hydrazide, PSA-hydrazine and aldehyde-activated dextran.

4. The method according to claim 1 wherein the carbohydrate moiety is oxidized by incubation in a buffer comprising NaIO 4 .

5. The method according to claim 1 wherein the oxidized carbohydrate moiety of FVIII is located in the B domain of Factor VIII.

6. A modified Factor VIII produced by the method according to any one of claims 1 - 5 .

7. A proteinaceous molecule comprising:

(a) a Factor VIII molecule; and

(b) at least one water soluble polymer bound to said Factor VIII molecule, wherein said water soluble polymer is attached to the Factor VIII via one or more carbohydrate moieties located in the B domain of Factor VIII, wherein said molecule retains at least 50% of native FVIII activity.

8. The proteinaceous molecule of claim 7 wherein the water soluble polymer is selected from the group consisting of PEG, PSA and dextran.

9. The method according to claim 1 wherein said FVIII that has been conjugated to the water soluble polymer retains at least 80% of native FVIII activity.

10. The molecule according to claim 7 wherein said molecule retains at least 80% of native FVIII activity.

Assignments (5)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 31, 2021
From: BAXALTA GMBH; BAXALTA INCORPORATED
To: TAKEDA PHARMACEUTICAL COMPANY LIMITED
Reel/Frame 055189/0005 →
CORRECTIVE ASSIGNMENT TO CORRECT THE CONVEYING PARTY DATA PREVIOUSLY RECORDED AT REEL: 036359 FRAME: 0631. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Aug 24, 2015
From: BAXTER HEALTHCARE SA
To: BAXALTA GMBH; BAXALTA INCORPORATED
Reel/Frame 036433/0699 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 17, 2015
From: BAXTER HEALTHCARE S.A.
To: BAXALTA GMBH; BAXALTA INCORPORATED
Reel/Frame 036359/0631 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 17, 2015
From: BAXTER INTERNATIONAL INC.
To: BAXALTA GMBH; BAXALTA INCORPORATED
Reel/Frame 036373/0001 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 9, 2008
From: TURECEK, PETER; SIEKMANN, JUERGEN
To: BAXTER INTERNATIONAL INC.; BAXTER HEALTHCARE S.A.
Reel/Frame 021950/0506 →